In contrast to previous studies that showed a correlation between HER2 overexpression and both lymph node metastasis and higher tumor stage [25,26], we found that 50% of HER2-overexpressed tumors were papillary predominant adenocarcinomas. Here, ERBB2 is linked to adenocarcinoma.